Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oral Oncology > Brand Names/MOA/Indications > Flashcards

Brand Names/MOA/Indications Flashcards

1
Q

alectinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Alecensa
(2) ALK and RET TKI
(3) ALK positive NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

thalidomide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Thalomid
(2) Angiogenesis inhibitor
(3) Multple Myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

olaparib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 4

A

(1) Lynparza
(2) PARP Inhibitor
(3) Ovarian, breast, pancreatic, and prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

palbociclib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Ibrance
(2) CDK 4/6 Inhibitor
(3) HR+/HER2- advanced/metastatic breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

cobimetinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Cotellic
(2) MEK Inhibitor
(3) Unresectable or metastatic melanoma with BRAF V600 E or V600K mutation (in combination with vemurafenib)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ibrutinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 5

A

(1) Imbruvica
(2) Bruton tyrosine kinase (BTK) inhibitor
(3) CLL/SLL, MCL, WM, chronic graft vs host disease, marginal zone lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

imatinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 2

A

(1) Gleevec
(2) BCR-ABL and cKIT TKI
(3) CML and GIST

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ribociclib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Kisqali
(2) CDK 4/6 Inhibitor
(3) HR+/HER2- advanced/metastatic breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

erlotinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Tarceva
(2) Early generation EGFR TKI
(3) Lung cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

neratinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Nerlynx
(2) EFGR, HER2, and HER 3/4 TKI
(3) HER2+ breast cancer post adjuvant HER2 directed therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

cabozantinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 2

A

(1) Cabometyx
(2) Multi-TKI inc. VEGF
(3) Renal cell and hepatocellular carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

temozolomide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Temodar
(2) Cytotoxic agent: alkylating agent
(3) Glioblastoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

niraparib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 3

A

(1) Zejula
(2) PARP Inhibitor
(3) Maintenance treatment in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

trametinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Mekinist
(2) MEK Inhibitor
(3) Unresectable or metastatic melanoma with BRAF V600E mutation (in combination with dabrafenib)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

gefitinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Iressa
(2) Early generation EGFR TKI
(3) Lung cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

rucaparib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 2

A

(1) Rubraca
(2) PARP Inhibitor
(3) Ovarian and prosate cancer

17
Q

capecitabine:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Xeloda
(2) Cytotoxic agent: antimetabolite
(3) Adjuvant therapy for colon cancer, metastatic colon cancer, rectal cancer, breast cancer

18
Q

afatinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Gilotrif
(2) Early generation EGFR TKI
(3) Lung cancer

19
Q

lapatinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Tykerb
(2) EGFR and HER2 TKI
(3) HER+ advanced or metastatic breast cancer in combination with:
a) capecitabine in patients who’ve previously
received an anthracycline, taxane, and trastuzumab
b) letrozole in patients eligible for hormonal therapy

20
Q

dabrafenib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Tafinlar
2) BRAF Inhibitor
(3) Unresectable or metastatic melanoma with BRAF V600E mutation (in combination with trametinib)

21
Q

enzalutamide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Xtandi
(2) Androgen receptor antagonist
(3) Non-metastatic and metastatic castration resistant prostate cancer

22
Q

apalutamide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Erleada
(2) Androgen receptor antagonist
(3) Non-metastatic castration resistant prostate cancer

23
Q

vemurafenib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Zelboraf
(2) BRAF Inhibitor
(3) Unresectable or metastatic melanoma with BRAF V600E mutation

24
Q

pomalidomide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Pomalyst
(2) Angiogenesis inhibitor
(3) Multple Myeloma

25
Q

abiraterone:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Zytiga
(2) CYP17 inhibitor - essential enzyme in androgen production
(3) metastatic, castrate-sensitive prostate cancer and metastatic, castrate-resistant prostate cancer

26
Q

pazopanib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 2

A

(1) Votrient
(2) Multi-TKI inc. VEGF
(3) RCC and soft tissue sarcoma

27
Q

venetoclax:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 2

A

(1) Venclexta
(2) Selective small molecule inhibitor of the anti-apoptotic protein beta cell lymphoma-2 (BCL-2)
(3) CLL and small lymphocitic leukemia

28
Q

osimertinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Tagrisso
(2) EGFR TKI including T790M mutation
(3) EFGR positive NSCLC q/ T790M mutation who have progressed on or after EGFR TKI therapy.

29
Q

abemaciclib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Verzenio
(2) CDK 4/6 Inhibitor
(3) HR+/HER2- advanced/metastatic breast cancer

30
Q

ruxolitinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Jakafi
(2) JAK1 & JAK2 inhibitor
(3) myelofibrosis, polycythemia vera (if inadequate response to hydroxyurea), aGVHD

31
Q

lenalidomide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Revlimid
(2) Angiogenesis inhibitor
(3) Multple Myeloma

32
Q

sorafenib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 2

A

(1) Nexavar
(2) Multi-TKI inc. VEGF
(3) RCC, hepatocellular carcinoma

33
Q

crizotinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

A

(1) Xalkori
(2) ALK Inhibitor
(3) ALK positive NSCLC

34
Q

sunitinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 3

A

(1) Sutent
(2) Multi-TKI inc. VEGF
(3) RCC, GIST, pancreatic neuroendocrine tumors

Oral Oncology (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions